BioCryst Pharmaceuticals(BCRX) - 2022 Q4 - Annual Report

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 par value BCRX Nasdaq Global Select Market Large accelerated filer x Accelerated filer o Non-accelerated filer oSmaller reporting company o Emerging growth company o UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 o TRANSITION RE ...